Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775424 · ClinicalTrials.gov registry record · Phase 1
PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00775424: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00775424 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00775424, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
A phase Ib partially blinded pilot study to evaluate the safety and immunological effects of PENNVAX-B with or without co-administration of constructs containing DNA encoding for the expression of either IL-12 or IL-15. Primary objectives 1. To determine the safety of HIV-1 DNA constructs (PENNVAX-B). 2. To determine the safety and optimal doses of the IL-12 and the IL-15 adjuvant constructs when given with PENNVAX-B. Secondary objectives 1. To compare the various vaccine groups for their immunological responses to several HIV-1 antigens, utilizing the ELISPOT assay. 2. To analyze antibody responses to the vaccine antigens over time. 3. To measure CD8 cell proliferative responses to vaccine antigens over time.
Interventions
- BIOLOGICAL PENNVAX-B
- BIOLOGICAL GENEVAX IL-12-4532
- BIOLOGICAL PLACEBO
- BIOLOGICAL IL-15 adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
What the finished NCT00775424 record still lists
NCT00775424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 4 interventions - of which PENNVAX-B is the first listed.
NCT00775424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00775424 about?
NCT00775424 is a clinical study titled "PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection". A phase Ib partially blinded pilot study to evaluate the safety and immunological effects of PENNVAX-B with or without co-administration of constructs containing DNA encoding for the expression of either IL-12 or IL-15. Primary objectives 1. To determine the safety of HIV-1 DNA constructs (PENNVAX...
What is the current status of trial NCT00775424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2008-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00775424?
The interventions under investigation include: PENNVAX-B (BIOLOGICAL), GENEVAX IL-12-4532 (BIOLOGICAL), PLACEBO (BIOLOGICAL), IL-15 adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00775424?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00775424's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia